Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onartuzumab + Paclitaxel + Platinum in Squamous NSCLC
NCT01519804Phase 2Completed
- Sponsor
- Genentech
- Start
- Apr 2012
- Primary completion
- Jan 2014
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in squamous cell carcinoma of the lung (SCCL) comparing MetMAb Arm with Placebo Arm (2 arms). Primary endpoints: Progression-Free Survival and Progression-Free Survival in Met-positive Subgroup. Started Apr 2012; status: completed.
02
Drugs
onartuzumab
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT01519804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01519804.